睿智医药
(300149)
| 流通市值：55.57亿 | | | 总市值：58.31亿 |
| 流通股本：4.75亿 | | | 总股本：4.98亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 533,797,976.84 | 261,261,312.24 | 970,204,758.8 | 718,525,731.65 |
| 营业收入 | 533,797,976.84 | 261,261,312.24 | 970,204,758.8 | 718,525,731.65 |
| 二、营业总成本 | 513,553,112.14 | 260,328,377.29 | 1,031,638,143.67 | 774,216,447.7 |
| 营业成本 | 378,921,265.51 | 189,559,932.03 | 758,697,970.95 | 580,392,041.96 |
| 利息支出 | - | - | 0 | - |
| 手续费及佣金支出 | - | - | 0 | - |
| 退保金 | - | - | 0 | - |
| 赔付支出净额 | - | - | 0 | - |
| 提取保险合同准备金净额 | - | - | 0 | - |
| 保单红利支出 | - | - | 0 | - |
| 分保费用 | - | - | 0 | - |
| 税金及附加 | 2,125,771.08 | 522,015.54 | 5,363,343.8 | 4,077,279.77 |
| 销售费用 | 25,031,453.84 | 11,246,944.27 | 36,406,561.7 | 28,332,227.32 |
| 管理费用 | 81,833,011.13 | 45,776,422.78 | 167,743,905.79 | 108,034,303.98 |
| 研发费用 | 24,722,034.39 | 12,101,507.4 | 59,550,940.69 | 45,275,069.93 |
| 财务费用 | 919,576.19 | 1,121,555.27 | 3,875,420.74 | 8,105,524.74 |
| 其中:利息费用 | 8,318,536.93 | 300,332.49 | 26,098,678.68 | 2,911,402.21 |
| 其中:利息收入 | 5,413,857.93 | 2,150,370.32 | 12,158,879.85 | 7,167,883.24 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -15,167.73 | -5,444.83 | -2,296,500 | 1,648.56 |
| 加:投资收益 | 12,893,493.74 | 1,941,186.55 | 10,091,924.67 | 7,301,977.95 |
| 净敞口套期收益 | - | - | 0 | - |
| 汇兑收益 | - | - | 0 | - |
| 资产处置收益 | 6,261,722.68 | 6,261,722.68 | 8,433,398.14 | 3,621,788.88 |
| 资产减值损失(新) | -1,635,582.6 | 1,847,630.6 | -156,882,554.07 | -13,627,814.85 |
| 信用减值损失(新) | -12,808,391.56 | -4,817,206.31 | -29,563,544.47 | -14,756,509.91 |
| 其他收益 | 6,730,733.46 | 3,206,031.52 | 14,813,479.08 | 6,591,864.4 |
| 四、营业利润 | 31,671,672.69 | 9,366,855.16 | -216,837,181.52 | -66,557,761.02 |
| 加:营业外收入 | 917,336.1 | 21,116.01 | 67,255.03 | 29,117.39 |
| 减:营业外支出 | 478,061.71 | 64,301.88 | 14,873,936.51 | 510,060.41 |
| 五、利润总额 | 32,110,947.08 | 9,323,669.29 | -231,643,863 | -67,038,704.04 |
| 减:所得税费用 | 6,765,580.85 | 2,700,270.94 | -5,131,547.83 | -5,256,354.55 |
| 六、净利润 | 25,345,366.23 | 6,623,398.35 | -226,512,315.17 | -61,782,349.49 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 25,345,366.23 | 6,623,398.35 | -226,512,315.17 | -61,782,349.49 |
| 终止经营净利润 | - | - | 0 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 25,382,118.44 | 6,642,081.65 | -226,474,828.03 | -61,667,008.36 |
| 少数股东损益 | -36,752.21 | -18,683.3 | -37,487.14 | -115,341.13 |
| 扣除非经常损益后的净利润 | 6,792,287.51 | -1,570,969.9 | -235,744,176.17 | -69,041,288.84 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.05 | 0.01 | -0.45 | -0.12 |
| (二)稀释每股收益 | 0.05 | 0.01 | -0.45 | -0.12 |
| 八、其他综合收益 | -374,978.77 | -272,754.98 | 3,689,524.72 | -9,433,940.61 |
| 归属于母公司股东的其他综合收益 | -374,978.77 | -272,754.98 | 3,689,524.72 | -9,433,940.61 |
| 九、综合收益总额 | 24,970,387.46 | 6,350,643.37 | -222,822,790.45 | -71,216,290.1 |
| 归属于母公司股东的综合收益总额 | 25,007,139.67 | 6,369,326.67 | -222,785,303.31 | -71,100,948.97 |
| 归属于少数股东的综合收益总额 | -36,752.21 | -18,683.3 | -37,487.14 | -115,341.13 |
| 公告日期 | 2025-08-29 | 2025-04-29 | 2025-04-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |